Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

ABSTRACT:

Background

Trastuzumab-based regimens are the historical standard first-line (1L) treatments for HER2+ advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma. With pembrolizumab recently approved in combination with trastuzumab and chemotherapy as 1L treatment for patients with a programmed death-ligand 1 combined positive score of 1 or higher, establishing real-world benchmarks for patients' real-world outcomes from the preimmunotherapy era is essential.

Objective

To assess the real-world treatment patterns and the clinical and economic impact of 1L trastuzumab-based regimens among patients with HER2+ advanced gastric/GEJ adenocarcinoma.

Methods

This retrospective study used the Surveillance, Epidemiology, and End Results-Medicare linked database (January 1,

SUBMITTER: Wang L 

PROVIDER: S-EPMC12728815 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature